NCT07137429 Platelet Volunteers, Longitudinal and Multi-omic Study
| NCT ID | NCT07137429 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Condition | Thrombosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-03-26 |
| Primary Completion | 2041-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2026-03-26 with a primary completion date of 2041-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Platelets are a type of blood cell that play a critical role in bleeding, forming blood clots, and healing. Researchers want to know more about platelets work in healthy people. They want to look at how platelets clump together, how blood clots, and how genes and proteins work. They also want to study how these processes change over time and how they are affected by factors such diet, exercise, weight, and new health problems. Objective: To study how platelets function in healthy people. Eligibility: Healthy people aged 18 years and older. Design: Researchers will review participants medical history. They will ask about the participant s family history and any drugs they take. Participants will have a clinic visit once every 6 or 7 months for 10 years. Each visit will be 2 to 3 hours. At each visit, participants will have several tests and procedures: A physical exam, including vital signs. Hip and ankle circumference will be measured. Urine collection. Blood tests. About 10 tablespoons of blood will be drawn. Participants will be asked to fast for 10 hours and avoid drugs like aspirin or Advil for 7 days before each draw. Some of the blood may be used for gene studies. Some may be used to create stem cells for research. Stem cells are cells that can be used to make other types of cells. Surveys and questionnaires. Participants will answer questions about habitual activity, diet, smoking, drugs and alcohol, sleep, illness, and other health issues. These surveys may be done online, via email, or by phone.
Eligibility Criteria
* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Stated willingness to comply with all study procedures, including fasting at least 10 hours before each blood draw * Stated willingness to refrain from aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) for 7 days prior to any visits * Age \>= 18 years * In good general health as evidenced by self-reported medical history EXCLUSION CRITERIA: An individual who, by self-report, meets the following criteria will be excluded from participation in this study: * Current pregnancy or lactation * Active malignancies known, active known auto-immune disease, known major CVD (e.g., heart attack, stroke, venous thromboembolism, heart failure), severe bleeding history, on regular P2Y12 inhibitors or other antiplatelet treatments for a clinical reason, uncontrolled hypertension or diabetes
Contact & Investigator
Andrew D Johnson, Ph.D.
PRINCIPAL INVESTIGATOR
National Heart, Lung, and Blood Institute (NHLBI)
Frequently Asked Questions
Who can join the NCT07137429 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Thrombosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07137429 currently recruiting?
Yes, NCT07137429 is actively recruiting participants. Contact the research team at jayson.grey@nih.gov for enrollment information.
Where is the NCT07137429 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT07137429 clinical trial?
NCT07137429 is sponsored by National Heart, Lung, and Blood Institute (NHLBI). The principal investigator is Andrew D Johnson, Ph.D. at National Heart, Lung, and Blood Institute (NHLBI). The trial plans to enroll 400 participants.